Form 4: ANI Pharma Exec Sells Shares Under 10b5-1 Plan

Krista Davis, SVP and Chief HR Officer at ANI Pharmaceuticals, sold 3,814 shares of common stock in February 2026 as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Krista Davis, SVP, Chief HR Officer of ANI Pharmaceuticals, Inc. (ANIP), reported sales of common stock.
• A total of 3,814 shares were sold across two transactions on February 19, 2026, and February 20, 2026.
• On February 19, 2026, 2,084 shares were sold at a price of $77.53 per share.
• On February 20, 2026, 1,730 shares were sold at a weighted average price of $77.99 per share, with individual trades ranging from $77.45 to $78.58.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Davis on September 18, 2025.
• Following these transactions, Ms. Davis beneficially owns 49,263 shares of ANI Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it is insider selling, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic timing, suggesting personal financial planning rather than a negative outlook on the company.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating pre-planning and reducing concerns about opportunistic insider trading.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived by investors as a lack of confidence, though this is mitigated by the 10b5-1 plan.

Risks

• No new risks identified directly from this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and typically do not provide broader industry context. These sales are specific to an individual executive's personal financial planning rather than reflecting a company-wide or industry-wide trend.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The sale of shares by a senior executive could be interpreted in various ways, but the 10b5-1 plan suggests it's part of routine financial management rather than a signal of company distress. The impact is likely minimal given the relatively small number of shares sold compared to the company's total outstanding shares.

Next Steps

• No specific future actions, events, or milestones for the company were mentioned in this Form 4 filing.

Key Dates

Recommendation

This Form 4 filing reports routine insider selling under a pre-arranged 10b5-1 plan. Such transactions are typically not indicative of new material information about the company's performance or future prospects. Therefore, it does not provide a basis for a change in investment recommendation, and a 'hold' stance is maintained pending further fundamental analysis.

Keywords

ANI Pharmaceuticals, ANIP, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Krista Davis, Executive Compensation